A comprehensive resource for understanding, calculating, and applying CJC-1295 dosages in research and therapeutic settings.
---
The dosage recommendations presented here are derived from peer-reviewed studies, clinical trials, and expert consensus. Researchers use these data to design protocols that balance efficacy with safety, ensuring reproducible results across laboratories and clinical applications.
---
CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) analogue. It stimulates the pituitary gland to produce endogenous growth hormone (GH), which in turn promotes the synthesis of insulin-like growth factor-1 (IGF-1). The compound exists in two forms: with a drug affinity complex (DAC) that prolongs its half-life, and without DAC for more rapid action.
---
Common adverse reactions include:
The calculator below estimates a daily dose based on body weight and desired IGF-1 elevation. Adjustments are necessary for individual pharmacodynamics.
Formula:
Daily Dose (µg) = Body Weight (kg) × 0.15 µg/kg
Example: A 70-kg subject → 10.5 µg/day
---
CJC-1295 DAC is typically administered via subcutaneous injection. The solution is reconstituted with bacteriostatic water to a concentration of 1 mg/mL, then aliquoted into syringes for precise dosing.
---
Standard research protocols recommend 0.5–2 µg/kg per day, depending on study objectives and subject tolerance. Higher doses may be used for short-term investigations but carry increased side-effect risk.
---
Injections are usually given in the morning to align with circadian GH release patterns, although timing can be flexible if consistent daily administration is maintained.
---
Once daily injections provide steady plasma concentrations. Some protocols use twice-daily dosing for acute studies or when higher peak levels are required.
---
Long-term safety data suggest cycles of 4–6 weeks, followed by a washout period of at least 2 weeks before re-initiation to mitigate receptor down-regulation and potential side effects.
---
Body Weight (kg) | Daily Dose (µg) |
---|---|
50 | 7.5 |
60 | 9.0 |
70 | 10.5 |
80 | 12.0 |
90 | 13.5 |
Without DAC, the peptide has a shorter half-life (~2–3 hours). The calculator assumes a more frequent dosing schedule.
Formula:
Daily Dose (µg) = Body Weight (kg) × 0.25 µg/kg
Example: A 70-kg subject → 17.5 µg/day
---
Similar to the DAC form, subcutaneous injections are used. Due to rapid clearance, doses may be split into multiple administrations per day.
---
Typical dosing ranges from 0.25–0.5 µg/kg per injection, with two to three injections daily depending on study design.
---
Injections are often spaced 6–8 hours apart to maintain therapeutic levels while avoiding peaks that could cause side effects.
---
Typically 2–3 times per day. Researchers monitor serum GH and IGF-1 to adjust frequency as needed.
---
Shorter cycles (2–4 weeks) are common, with a washout period of 1–2 weeks before repeat dosing.
---
Body Weight (kg) | Dose per Injection (µg) |
---|---|
50 | 12.5 |
60 | 15.0 |
70 | 17.5 |
80 | 20.0 |
90 | 22.5 |
Combining CJC-1295 with Ipamorelin (a selective ghrelin receptor agonist) synergistically enhances GH release.
Formula:
Daily Dose of CJC-1295 = Body Weight (kg) × 0.15 µg/kg
Daily Dose of Ipamorelin = 1.5–2.0 mg/day
Example: A 70-kg subject → 10.5 µg CJC-1295 + 2 mg Ipamorelin
---
Both peptides are injected subcutaneously, often in the same session. Reconstitution with bacteriostatic water and careful mixing ensures stability.
---
CJC-1295: 0.15 µg/kg/day
Ipamorelin: 1.5–2.0 mg/day (split into two injections if necessary)
---
Morning injections are preferred, but dosing can occur at any time as long as consistency is maintained.
---
Once daily for CJC-1295; Ipamorelin may be given twice daily (morning and evening) to sustain GH pulsatility.
---
Cycles of 4–6 weeks are typical, with a 2-week washout before re-initiating treatment.
---
Body Weight (kg) | Daily CJC-1295 Dose (µg) | Daily Ipamorelin Dose (mg) |
---|---|---|
50 | 7.5 | 1.8 |
60 | 9.0 | 2.0 |
70 | 10.5 | 2.0 |
80 | 12.0 | 2.2 |
90 | 13.5 | 2.4 |
When purchasing peptides, it is crucial to verify supplier credibility and product purity.
The optimal dosage depends on research goals, subject characteristics, and safety considerations. For valley.md most studies:
No Data Found!